Back to search

Peptide record

TPDB10917

ChMAP-28 ChMAP-29 Antibacterial Anticancer Toxicity standard

27 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB10917

Peptide_Name

ChMAP-28 ChMAP-29

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 Peptipedia CancerPPD 2.0 dbACP ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 27-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.

Sequence

GRFKRFRKKLKRLWHKVGPFVGPILHY

FASTA

>TPDB10917|Antibacterial;Anticancer;Toxicity|length=27
GRFKRFRKKLKRLWHKVGPFVGPILHY

Formula C163H255N49O29

Absent Amino Acids ANDCEQMST

Common Amino Acids K

Mass 3365.13

PI 12.43

Basic Residues 11

Acidic Residues 0

Hydrophobic Residues 11

Net Charge +9

Boman Index 3.01

Hydrophobicity -0.659

Aliphatic Index 79.26

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 6990

Absorbance 280nm 207.72

Polar Residues 1

number

Amino Acid Distribution

A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 2 I: 1 L: 3 K: 5 M: 0 F: 3 P: 2 S: 0 T: 0 W: 1 Y: 1 V: 2

Length

Formula

C163H255N49O29

Mass

3365.13

12.43

Net Charge

Boman Index

3.01

Hydrophobicity

-0.659

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

leucocytes of the goat Capra hircus

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 3.39 ± 0.15 µM

Detail Source Activity Anticancer

Activity Measurement 3.39

Target

Cancer Type Leukemia Cancer

Cell Line HL-60

Tissue Affected Blood

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Raw

~60% LDH Release at 2.5 µM

Detail Source Activity Anticancer

Target

Cancer Type Leukemia Cancer

Cell Line HL-60

Tissue Affected Blood

Assay & Model

Assay LDH leakage assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 6.49 ± 0.09 µM

Detail Source Activity Anticancer

Activity Measurement 6.49

Target

Cancer Type Skin Cancer

Cell Line A-431

Tissue Affected Skin

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 5.09 ± 0.40 µM

Detail Source Activity Anticancer

Activity Measurement 5.09

Target

Cancer Type Renal Cancer

Cell Line HEK-293T

Tissue Affected Renal

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 5.63 ± 1.05 µM

Detail Source Activity Anticancer

Activity Measurement 5.63

Target

Cancer Type Breast Cancer

Cell Line SK-BR-3

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4.82 ± 1.01 µM

Detail Source Activity Anticancer

Activity Measurement 4.82

Target

Cancer Type Skin Cancer

Cell Line B16-F10

Tissue Affected Skin

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 7 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 100 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Evidence 8 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 8.95±2.68 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 8.95±2.68 | µM | target cell: Human embryonic fibroblasts

Target

Target Cell Human embryonic fibroblasts

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Anticancer Activity of the Goat Antimicrobial Peptide ChMAP-28. | Front Pharmacol | 2018

Evidence 9 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement >10 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | >10 | µM | target cell: Human normal astrocytes

Target

Target Cell Human normal astrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Anticancer Activity of the Goat Antimicrobial Peptide ChMAP-28. | Front Pharmacol | 2018

Evidence 10 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 5.09±0.40 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 5.09±0.40 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Target Cell Human embryonic kidney HEK293T cells

Source & Reference

Database Source NA

Source Database DBAASP

Evidence 11 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 4.6 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 4.6 | µM | target cell: Human PBMC

Target

Target Cell Human PBMC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Anticancer Activity of the Goat Antimicrobial Peptide ChMAP-28. | Front Pharmacol | 2018

Evidence 12 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 5.4±1.38 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 5.4±1.38 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Dodecapeptide Cathelicidins of Cetartiodactyla: Structure, Mechanism of Antimicrobial Action, and Synergistic Interaction With Other Cathelicidins. | Front Microbiol | 2021

Evidence 13 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 5.09

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

Hemolytic_activity: Human erythrocytes: ChMAP-28 has a low hemolytic activity (hemolysis less than 10%) at a concentration range up to 10 µM. | Cytotoxicity: HEK293T: IC50=5.09±0.40 µM HEF: IC50=8.95±2.68 µM

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Front Pharmacol. 2018 Dec 21 9:1501.